Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Pertuzumab and trastuzumab (SC, as PHESGO)",HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with docetaxel,"Pertuzumab and trastuzumab (SC, as PHESGO) (PHESGO)",Community and Hospital,Oncology Agents and Immunosuppressants
